Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting
Launched by PHILIP MORRIS PRODUCTS S.A. · Oct 26, 2013
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is Japanese.
- • Smoking, healthy subject as judged by the Investigator.
- • Subject smokes at least 10 commercially available non-menthol CCs per day (no brand restrictions) for the last 4 weeks, based on self reporting.
- • Subject has smoked for at least the last 3 consecutive years.
- • Subject does not plan to quit smoking in the next 3 months.
- Exclusion Criteria:
- • As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
- • The subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.
- • For women: Subject is pregnant or is breast feeding.
- • For women: Subject does not agree to use an acceptable method of effective contraception.
About Philip Morris Products S.A.
Philip Morris Products S.A. is a leading global tobacco and nicotine product manufacturer, dedicated to transforming its business by developing and promoting smoke-free alternatives. With a strong emphasis on research and innovation, the company invests significantly in scientific studies to understand the health impacts of its products and to explore alternatives that reduce harm associated with traditional smoking. As a responsible industry leader, Philip Morris Products S.A. actively engages in clinical trials to evaluate the safety and efficacy of its reduced-risk products, contributing to the evolving landscape of tobacco harm reduction and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Takuya Kunito, MD
Principal Investigator
Higashi Shinjuku Clinic
Christelle Haziza, PhD
Study Chair
Philip Morris Products S.A.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials